Advertisement

Oropharynx Cancer

  • Nikhil P. JoshiEmail author
  • Martin C. Tom
Chapter

Abstract

Two distinct types of oropharynx cancer have emerged over the last few years, namely HPV related and HPV unrelated oropharynx cancer. HPV related oropharyngeal carcinoma has a separate staging system and these cancers generally do better than their stage matched HPV unrelated counterparts. This chapter focuses on history, examination, evaluation, and management of oropharynx cancers with an emphasis on the role of radiation.

Keywords

Oropharynx cancer Human papillomavirus Radiotherapy Intensity modulated radiotherapy 

References

  1. 1.
    NCCN Clinical Practice Guidelines in Oncology: Smoking Cessation. https://www.nccn.org/professionals/physician_gls/pdf/smoking.pdf. 2018. Accessed 23 Dec 2018.
  2. 2.
    Eisbruch A, Harris J, Garden AS, et al. Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). Int J Radiat Oncol Biol Phys. 2010;76(5):1333–8.CrossRefGoogle Scholar
  3. 3.
    Pignon JP, le Maitre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4–14.CrossRefGoogle Scholar
  4. 4.
    Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–78.CrossRefGoogle Scholar
  5. 5.
    Gillison ML, Trotti AM, Harris J, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019;393:40.CrossRefGoogle Scholar
  6. 6.
    Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48(1):7–16.CrossRefGoogle Scholar
  7. 7.
    Lacas B, Bourhis J, Overgaard J, et al. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol. 2017;18(9):1221–37.CrossRefGoogle Scholar
  8. 8.
    Gregoire V, Evans M, Le QT, et al. Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. Radiother Oncol. 2018;126(1):3–24.CrossRefGoogle Scholar
  9. 9.
    Yeung AR, Garg MK, Lawson J, et al. ACR Appropriateness Criteria(R) ipsilateral radiation for squamous cell carcinoma of the tonsil. Head Neck. 2012;34(5):613–6.CrossRefGoogle Scholar
  10. 10.
    Mehanna H, Wong WL, McConkey CC, et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. N Engl J Med. 2016;374(15):1444–54.CrossRefGoogle Scholar
  11. 11.
    Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409.CrossRefGoogle Scholar
  12. 12.
    Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24–35.CrossRefGoogle Scholar
  13. 13.
    O’Sullivan B, Huang SH, Siu LL, et al. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol. 2013;31(5):543–50.CrossRefGoogle Scholar
  14. 14.
    Edge SB. American Joint Committee on Cancer. AJCC cancer staging manual. 8th ed. New York: Springer; 2017.Google Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  1. 1.Cleveland Clinic FoundationClevelandUSA

Personalised recommendations